<SEC-DOCUMENT>0001654954-18-003636.txt : 20180405
<SEC-HEADER>0001654954-18-003636.hdr.sgml : 20180405
<ACCEPTANCE-DATETIME>20180404174634
ACCESSION NUMBER:		0001654954-18-003636
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20180403
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180405
DATE AS OF CHANGE:		20180404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		18738383

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cvm_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times\ New\ Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">UNITED
STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">WASHINGTON, D.C.
20549</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">FORM
8-K</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">CURRENT
REPORT</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to Section
13 or 15(d) of the</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Securities Exchange
Act of 1934</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">Date of
Report (date of earliest event reported): April 3,
2018</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">
CEL-SCI CORPORATION</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">(Exact
name of Registrant as specified in its charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-family: inherit; font-size: inherit;">
<tr>
<td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center"><font style="font-size: 13px">&#xA0;Colorado</font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center"><font style="font-size: 13px">&#xA0;001-11889</font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center"><font style="font-size: 13px">&#xA0;84-0916344</font></div>
</td>
</tr><tr>
<td style="width: 20%">
<div style="text-align: center"><font>&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">(State or other
jurisdiction</font> <font style="font-family: Times New Roman; font-size: 13px">of
incorporation)</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 20%">
<div style="text-align: center"><font>&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">(Commission File
No.)</font></div>
</td>
<td style="width: 1%;">
<div><font>&#xA0;</font></div>
</td>
<td style="width: 20%">
<div style="text-align: center"><font>&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">(IRS Employer
Identification No.)<br></font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8229
Boone Boulevard, Suite 802</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">Vienna,
Virginia&#xA0; 22182<br></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;(Address
of principal executive offices, including Zip Code)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Registrant&#x2019;s
telephone number, including area code:&#xA0;&#xA0;&#xA0; (703)
506-9460</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;<br>
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">N/A<br>
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Former
name or former address if changed since last report)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">&#x2610;
<font style="font-family: Times\ New\ Roman; font-size: 13px;">Written
communications pursuant to Rule 425 under the Securities Act (17CFR
230.425)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">&#x2610;
<font style="font-family: Times\ New\ Roman; font-size: 13px;">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">&#x2610;
<font style="font-family: Times\ New\ Roman; font-size: 13px;">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px;">&#x2610;
<font style="font-family: Times\ New\ Roman; font-size: 13px;">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-14c))</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (&#xA7;203.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (&#xA7;204.12b-2 of this chapter.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company &#x2610;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. &#x2610;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: rgb(255, 255, 255);">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
3.03.&#xA0;&#xA0;&#xA0; Material Modification to Rights of Security
Holders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
April 3, 2018 the exercise price of the Company&#x2019;s outstanding
Series S warrants (CUSIP number 150837177), that are publicly
traded under the symbol &#x201C;CVM WS&#x201D; on the NYSE American,
was changed to $1.75 per share until June 11, 2018. After this
date, the exercise price will revert back to $31.25 per share of
common stock. As a result of the reverse stock split which became
effective on the NYSE American on June 15, 2017, 25 Series S
warrants are required to purchase one share of common stock. The
Series S warrants expire on October 11, 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company issued a press release, filed as Exhibit 99.1, announcing
the repricing of the exercise price of the Series S
warrants.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
8.01&#xA0;&#xA0;&#xA0; Other Events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">On
April 4, 2018, the Company issued a press release, filed as Exhibit
99.2, providing an updated on the status of the Phase 3 clinical
study and the arbitration suit the Company filed against the former
clinical research organization for our Phase 3 trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
9.01.&#xA0;&#xA0;&#xA0; Financial Statements and
Exhibits.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-family: inherit; font-size: inherit;">
<tr>
<td style="width: 12%; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size: 13px"><font style="font-weight: bold;">Exhibit</font></font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 13px"><font style="font-weight: bold;">&#xA0;</font></font></div>
</td>
<td style="width: 87%; border-bottom: 2px solid rgb(0, 0, 0);">
<div><font style="font-size: 13px"><font style="font-weight: bold;">Description</font></font></div>
</td>
</tr><tr>
<td style="width: 12%;">
<div><font style="font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 87%;">
<div><font style="font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="width: 12%;">
<div><font style="font-size: 13px"><a href="cvm_ex991.htm"><font>99.1</font></a></font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 87%;">
<div><font style="font-size: 13px"><font style="font-family: Times\ New\ Roman;">Press Release dated April 3,
2018</font></font></div>
</td>
</tr><tr>
<td style="width: 12%;">
<div><font style="font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 87%;">
<div><font style="font-size: 13px">&#xA0;<font style="font-family: Times\ New\ Roman;">&#xA0;</font></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="width: 12%;">
<div><font style="font-size: 13px"><a href="cvm_ex992.htm"><font>99.2</font></a></font></div>
</td>
<td style="width: 1%;">
<div><font style="font-size: 13px">&#xA0;</font></div>
</td>
<td style="width: 87%;">
<div><font style="font-size: 13px"><font style="font-family: Times\ New\ Roman;">Press Release dated April 4,
2018</font></font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">CEL-SCI
CORPORATION</font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<font style="font-family: Times New Roman; font-size: 13px">Date:
April 4, 2018</font></td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/</font>
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten<br></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font></td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
Chief Executive Officer<br></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;"><br>
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<br>
</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cvm_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times\ New\ Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr"></div>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: right; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 24px"><font style="color: #7F7F7F">
</font></font></div>
<div style="text-align: right; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px"><font style="font-family: Times\ New\ Roman;"><font style="font-weight: bold">Exhibit
99.1</font><br></font></font></div>
<div style="text-align: right; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: right; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 24px"><font style="color: #7F7F7F">
N</font><font style="font-variant: small-caps; color: #7F7F7F">EWS
RELEASE</font></font></div>
<div style="text-align: right; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 24px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">

<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="cvm_ex991000.jpg"></div>
</div>
</div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--line--><br></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 47%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">8229
Boone Boulevard, Suite 802</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Vienna,
VA 22182. USA</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Telephone
(703) 506-9460</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">www.cel-sci.com</font></div>
</td>
<td style="vertical-align: top; width: 53%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">COMPANY
CONTACT:</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 192px">
<font style="font-family: Times New Roman; font-size: 13px">Gavin
de Windt</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 192px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 192px">
<font style="font-family: Times New Roman; font-size: 13px">(703)
506-9460</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI ANNOUNCES ADJUSTMENT TO WARRANT EXERCISE PRICE</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Vienna, VA, April 3, 2018</font> &#x2013; CEL-SCI Corporation
<font style="font-weight: bold">(NYSE American: CVM)</font>
announced today that the outstanding Series S warrants (CUSIP
number 150837177) that are publicly traded under the symbol
&#x201C;CVM WS&#x201D; on the NYSE American have been repriced to
$1.75 per share of common stock until June 11, 2018. After this
date, the exercise price will revert back to $31.25 per share of
common stock. Twenty-five (25) warrants are required to purchase
one share of common stock. The warrants expire on October 11,
2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About CEL-SCI Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
is a Phase 3 cancer immunotherapy company. When it comes to cancer
immunotherapy, CEL-SCI believes it is most logical to boost the
patient&#x2019;s immune system while it is still intact in order to
have the greatest possible impact on survival. Therefore, CEL-SCI
treats patients who are newly diagnosed with head and neck cancer
with its lead investigational immunotherapy Multikine* (Leukocyte
Interleukin, Injection), BEFORE they have received surgery,
radiation and/or chemotherapy, at a time when the immune system
should be at its strongest. This approach is unique. Most other
cancer immunotherapies are used only after conventional therapies
have been tried and/or failed. Head and neck cancer represents
about 6% of all cancers. Multikine has received Orphan Drug
designation from the FDA for the treatment of head and neck cancer
patients with advanced squamous cell carcinoma.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #181818">
The Company&#x2019;s LEAPS technology is being developed as a
potential therapeutic vaccine for rheumatoid arthritis and is
supported by a grant from the</font> National Institute of
Arthritis and Musculoskeletal and Skin Diseases of the <font style="color: #181818">National Institutes of Health. The Company has
operations in Vienna, Virginia, and in/near Baltimore,
Maryland.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
When used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability
to duplicate the clinical results demonstrated in clinical studies,
timely development of any potential products that can be shown to
be safe and effective, receiving necessary regulatory approvals,
difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI&#x2019;s filings with
the Securities and Exchange Commission, including but not limited
to its report on Form 10-K for the year ended September 30, 2017.
The Company undertakes no obligation to publicly release the result
of any revision to these forward-looking statements which may be
made to reflect the events or circumstances after the date hereof
or to reflect the occurrence of unanticipated events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in
progress.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>cvm_ex992.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times\ New\ Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr"></div>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 32px"><font style="color: #7F7F7F">
</font></font></div>
<div style="text-align: right; margin-left: 12px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 32px;"><font style="font-size: 13px">&#xA0;<font style="font-weight: bold">Exhibit
99.2</font></font><br></font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 32px"><font style="color: #7F7F7F">
N</font><font style="font-variant: small-caps; color: #7F7F7F">EWS
RELEASE</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font><img src="cvm_ex992000.jpg"></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--line--><br></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div><font>&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0 auto;width: 100%;; font-family: inherit; font-size: inherit">
<tr>
<td style="width: 50%">
<div><font style="font-family: Times New Roman; font-size: 13px">8229 Boone
Boulevard, Suite 802</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px">Vienna, VA 22182.
USA</font><br>
<font style="font-family: Times New Roman; font-size: 13px">Telephone (703)
506-9460</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px">www.cel-sci.com</font></div>
</td>
<td style="width: 50%">
<div><font>&#xA0;</font><font style="font-family: Times New Roman; font-size: 13px">COMPANY
CONTACT:</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px">Gavin de
Windt</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
Corporation</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px">(703)
506-9460</font></div>
</td>
</tr></table>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 16px">CEL-SCI
CORPORATION ISSUES LETTER TO SHAREHOLDERS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Vienna, VA, April 4, 2018 --</font> CEL-SCI Corporation
<font style="font-weight: bold">(NYSE American: CVM)</font> today
issued a letter to its shareholders.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Dear
Fellow Shareholders,</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We have
achieved significant progress towards completing and reporting
results on our Phase 3 head and neck cancer study for our lead
investigational immunotherapy Multikine* (Leukocyte Interleukin,
Injection). The study is fully enrolled. We are following the study
subjects for outcomes and will be able to analyze all of the data
for safety and efficacy when 298 deaths have occurred in the two
main comparator arms of the study and the corresponding data have
been recorded in the study database. Based on overall survival data
available in the scientific literature for the study&#x2019;s
patient population, advanced primary head and neck cancer patients,
and the fact that all of the patients in our Phase 3 study were
enrolled between 2011 and September 2016, the time when 298 deaths
will be reached in the combined comparator arms of the study should
be near.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
primary efficacy endpoint of the study is a 10% improvement in
overall survival of the Multikine treatment regimen plus Standard
of Care (SOC) vs. Standard of Care alone. Late last year, the
study&#x2019;s Independent Data Monitoring Committee (IDMC)
completed a review of the data from all 928 patients enrolled in
the study and found no evidence of any significant safety questions
and recommended the study continue as constituted. Once completed,
should the study meet its primary efficacy endpoint of 10%
improvement in overall survival, CEL-SCI plans to apply for
regulatory approval in major markets including the United States
and the European Union. Head and neck cancer accounts for about 6%
of all cancers worldwide.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In the
$50 million-plus arbitration suit we filed against the former
clinical research organization (CRO) for our Phase 3 trial, we are
pleased to report that during the past few months, both parties
have filed their closing briefs and subsequently also their
responsive briefs. That only leaves the closing arguments which are
scheduled to be delivered this month, April 2018. This final stage
of the arbitration will take place on two consecutive days, with
one party presenting their closing arguments one day and the other
party presenting the next day. The arbitration suit was filed in
October 2013 by CEL-SCI, seeking at least $50 million from the CRO
that originally ran the Phase 3 head and neck cancer study.
CEL-SCI's arbitration claim alleges (i) breach of contract, (ii)
fraud in the inducement, and (iii) common law fraud. We look
forward to a productive end to the arbitration suit in the near
term.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI&#x2019;s
clinical development program for our LEAPS (Ligand Epitope Antigen
Presentation System) vaccine platform technology continues to
advance with the support of a $1.5 million grant from the U.S.
National Institutes of Health (NIH) to develop CEL-4000, our
rheumatoid arthritis candidate treatment vaccine, the first product
based on our LEAPS platform. Data from pre-clinical studies
currently being conducted will be used in support of an
Investigational New Drug (IND) application we plan to file with the
FDA for CEL-4000. CEL-SCI was recently issued a patent from the US
Patent and Trademark Office for our LEAPS platform
technology.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">1</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In the
near term, we look forward to the completion of our arbitration
suit against the former CRO and we also look forward to receiving
results on both the completion and corresponding top line data on
our Phase 3 head and neck cancer trial.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We
thank you for your continued support of our Company.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sincerely,</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Chief
Executive Officer</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About CEL-SCI Corporation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
is a Phase 3 cancer immunotherapy company. The Phase 3 study is
fully enrolled with 928 patients. When it comes to cancer
immunotherapy, CEL-SCI believes it is most logical to boost the
patient&#x2019;s immune system while it is still intact in order to
have the greatest possible impact on survival. Therefore, CEL-SCI
treats patients who are newly diagnosed with head and neck cancer
with its lead investigational immunotherapy Multikine (Leukocyte
Interleukin, Injection), BEFORE they have received surgery,
radiation and/or chemotherapy. This approach is unique. Most other
cancer immunotherapies are used only after conventional therapies
have been tried and/or failed. Head and neck cancer represents
about 6% of all cancers. Multikine has received Orphan Drug
designation from the FDA for the treatment of head and neck cancer
patients with advanced squamous cell carcinoma. CEL-SCI has
received patents for Multikine from the US, Europe, China and
Japan.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s LEAPS technology is being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by
grants from the National Institutes of Health. The Company has
operations in Vienna, Virginia, and in/near Baltimore,
Maryland.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">This
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
When used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability
to duplicate the clinical results demonstrated in clinical studies,
timely development of any potential products that can be shown to
be safe and effective, receiving necessary regulatory approvals,
difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI&#x2019;s filings with
the Securities and Exchange Commission, including but not limited
to its report on Form 10-K for the year ended September 30, 2017.
The Company undertakes no obligation to publicly release the result
of any revision to these forward-looking statements which may be
made to reflect the events or circumstances after the date hereof
or to reflect the occurrence of unanticipated events.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in
progress.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>cvm_ex991000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_ex991000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !H -L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:[K&C.[!549+$X %.JCK
M-B^I:1<V:/L>5,!CTSUY]J<4FTF14E*,&XJ[["V6KZ?J,C1VEW',Z<E5/-0>
M(#J@TPG2 #<;AGIG;WQGC-<WX8\*ZCIVL+>7>R-(U( 5\E\C'Y5W%=%6-.E5
M7LWS(X<+.OBL,_;Q<).ZTT?KY%73?M9TVW-^%%UL_>;>F:M445SMW=SOA'EB
MHWO8****104444 %%%% !1110 4444 %%<)XQU^^M]46PLYV@144LR<%B??T
MIX\,^)2 ?[<//_39ZZUA;04YR2N>5+,VZLJ5&FY<N]K'<45Q'_",>)?^@X?^
M_P ]17.@>([2UEN6UMBL2%R!,^3@9H6'IO3VB_$'F%=*[H2^]'>45Q_@G7+S
M46N+2\E,QC4.CMUQG!!]:Z74-1M=+MQ/>2^7&6"@X)Y_"LJM"=.I[-ZLZL-C
M*5>@JZTCY]"W16%_PF&A_P#/[_Y#;_"C_A,-#_Y_?_(;?X4?5ZO\K^X/KV%_
MY^1^]&[16%_PF.A?\_O_ )#;_"M9[R".Q-XSXMPGF%\'[N,YJ)4IQ^)-&M/$
MT:E^2:=M[,GHJAIVL6.K>9]BF\SR\;OE(QGIU^E7ZF47%VDK%PJ1J1YH.Z\C
MEO%OB2XT=H;:T51-(N\NXR%&<<#UIOA+Q+<ZO-+:7BJ943>LB#&1G!!'XUJ:
M[X>M==2/S6>*6/[DB=<>A]13-$\/6?A^.61)&>1Q\\LF!@>GL*[.?#_5^6WO
MGDNCC_K_ +3F_=?\#MW\S:HJ""\M;EBL%S#*1U".#C\JGKC::W/8C)25T[A1
M7'^/]?O-&T^VBL9/*FN&;,@&2J@=OS%8]IX;\67]G!>+XC95GC$@!FDR 1GM
M2&>D45Y[_P (?XN_Z&0_]_I*/^$0\7?]#(?^_P!)0!Z%17GW@?Q!J=QK5SI.
MH7#72QJVV1ADJRG!Y[@^]>@T %%8EWXOT&QN&@GU&,2H<,J@M@_@*K_\)WX<
M_P"@B/\ OT_^% '1T5SG_"=^'/\ H(C_ +]/_A6KINLZ=JZ,]A=QSA/O!>J_
M4'F@"]16?JFMZ=HJ1-J%P(1*2$)4G)'7H*M6EW#?6D5U;/OAE7<C8QD4 >:^
M-/\ D:9/]R/^5>G)]Q?I7F/C3_D:I/\ <C_E7IR?<7Z5Z&+_ (-+T_R/ RK_
M 'S$_P"+_,=45U;K=6LUNY(65"A(Z@$8J6JNI326^F74T1Q)'$S*<9P0*X(W
MNK'N3:4&Y;%+1_#ECHDCR6OFF1UVLSOGBLWQ]_R (_\ KX7^1J/PCXBO]8NI
MX+SRB(XPX95P<YQ3_'W_ " (_P#KX7^1KNA&I'%Q51W=SQJM2A4RN<L.K1LR
MCX7L-"N-#CDOX[1IR[9,K -C/'>MG^RO"V<>3I__ 'V/\:Y_PWX4T[5M&CN[
MDSB1G8'8X X/TK77P'HZL&#7.0<_ZP?X5I7E3]I*\VM?ZZF&"I5WAX-48-66
MK>OY&E_PC&B?] V#_OFG:ZBQ>&KV-%"HMNRJ!V %:E9OB#_D7M0_ZX-_*N*$
MY2G'F=]3V*U&G3HSY(I:/9>1S'P[_P"8A_P#_P!FKN:X;X=_\Q#_ (!_[-7<
MUMC_ />)?UT.3(_]PA\_S85PWQ!N[A/LEHI98) SMC^(C'!KN:HZII-IK%KY
M%VA(!RK*<,I]0:RPU2-.JIR6ATYCAYXC#2I4W9L\@M+F:SNX[BW8I*C94C^5
M>UQL6C5F&"0"1Z5SNG>"M-L+I;AFEN&0Y02$8!]<#K725T8[$4ZTER=#@R3+
MZ^#A+VSWZ' _%"SFEL;&ZC1FCA=UD(&=NX#!/MQ5?3?B3I]CIEK:-97#-#$L
M98,N"0,>M=+KOB_3=#NQ97,<TLSJ&V(@(P>.236K_9>G-\QL+4D^L*_X5PGN
M''_\+3T[_GPN?^^E_P :/^%IZ=_SX7/_ 'TO^-=A_9.F_P#0/M?^_*_X4?V3
MIO\ T#[7_ORO^% &5X<\3:1K;20V,9MYU&]HF0*2,\D8X-;TQ(@D(."%)'Y5
MY3X3 3XD2J@"J'N%P.!CGBO59_\ CWE_W#_*D!Y)X!T^TU37;F*^MTN$$!<"
M09^;<.?UKT7_ (1'P_\ ] FV_P"^*X+X9?\ (QW/_7J?_0EKU>FP,0^$?#^#
MC2;;/^[7+^!_#FL:5KTMU=VOD6SQ,G+@D\@C@&O0B< GTKF?#_C6VU[46L4L
MYH955FRS K@'%(#%^*?_ !ZZ9_UTD_D*ZCPE_P BGIG_ %P6N7^*?_'IIG_7
M23^0KJ/"7_(IZ9_UP6@"AXE\*-K-REW;3K%.%"L'!PV.G(Z&L[_A'O%8X_M?
M_P CM_A71R:E<'5)K.$V:^65 $TI#OD \#%6[G4K2TD,<\VUPF\J%).WUX'3
MBNJ&+J1BHZ-+NCS:N58>I4=35-[V;1R/_"/>+/\ H+_^1V_PIK^&O%,J-')J
MP9&&&!F8@C\J[&WU&TNY3'!,'8+O& <%?4'H1]*2WU.SNG1(9MQ<'8=I ;'7
M!(P:KZ[4[+[C/^QZ'\TO_ F97AGPW_823/+,)9Y0 2HP% ["I?%&DW&LZ6MM
M;-&KB4/ER0, '_&M)=0M7N?LZR@R;BO0X+#J,],^U*+^U,D<?G+OD=D1>Y9?
MO#\,5C[>;J>U;U.M8*BL/]62M$XZT\/>*;&W$%KJ,,40)(4-Z_\  :G_ +)\
M8_\ 06B_[Z_^QKJ&U&U6*.7S<K*-R;5))'<X SCWHGU&TMQ"9)U'G#,6 27Z
M=,=>HK5XR;=VE]QS1RFE%<L9R2_Q,Y;^R?&/_06B_P"^O_L:Z&YL[JY\/26<
MDBM=26^QG)X+8Y-6C=(LEP'= L*!VY.0"">?RIMMJ-K=N5AEW$*'Y4C*^HSU
M'TK.=>4K.R5NR-Z6!A34ES2=U;5MG%67A3Q'IV_['?00[\;MKGG'3M5O^Q_&
M'_07C_[[_P#L:ZF'4[2>98HI2SN"4^1@& ZD'&"/>GWMR;2W\T+N^=$QG'WF
M"_UK26-J2=VE]QSPR>C"/+&4DO\ $SD_['\8?]!>/_OO_P"QKJ]/CN(M/@CN
MY!)<*@$CC^(^M-N=2L[20QSS;7";RH4DA>>>!TX-+;ZA:W4K1P3!V"[NA *^
MH/<>XK*I6=16:2]%8ZL/@X4).492=^[;+5%9XUO3FV[;G=O&4PC'?]..3["K
M$=[;2QP2)*"LYQ&<'YC@G'Z'\JQ.LYOQ=X.;Q#/#=VURL%U&NP[QE6&<CIT(
MK&_X1?QL.!KW_DP_^%=Y)J%K%"\SS*(TD\MFP>&SC'YT1W]K)!).)<1Q'#EE
M*E3[@\]Q0!P?_"+^-O\ H._^3#_X4?\ "+^-O^@]_P"3#_X5Z!!<Q7(8Q,25
M.&5E*E3[@\U7N[FX2]@MK9(BTB.Y,C$ ;2H[?[U '-^%O!<NBZC)J5_=K<73
M*0H0' SU))ZFNP8!E*GD$8-4[?44>"=[A1 ]N_ERKG(!X(P>X((Q]:9=ZM!;
M:9/>(&D\K@IM((;T(QD?E0!Q*>!-=TF_EGT75(8U?*@MD-M)S@\$58_L/QW_
M -!R'_OK_P"QKLVOX888FN'"NZ;R%5C@=SC&0/<XI9]1M;9E627YG4NH52Q*
MCN,#WI@<7_8?CO\ Z#D/_?7_ -C5[PCX-ET&\FOKRYCEN'38JQ@X4$Y)R>IX
MKII-0M8HXG,N5E7<FQ2Q9>N< =.1S3IKVW@5#(Y^<94*I8D=S@=J0'.^-?#E
M[XB@LTLWA4PNQ;S21U Z8%;6A6,NFZ'9V4Q4RPQ!&*GC/M4\NH6L*QLTN1(N
MY=BELKZ\=N1S5@$$ CH>E &6]E>)J-Q<VZV;B4JP,H.Y2% ZCZ5/-8O+<3R[
MU'FVWDXQT.6Y^G-7J* *4%BT-Q;2%P1#;>20!U.5Y_\ ':HZ997K6NGK<^6D
M5O\ .% (<G! !STQG\:VZ* ,I-,G5HH3)']EBG,ZD [SR6VGMU/6H;S0GN)[
MJ:*Y\MI-IA^7/E-_&?\ @0 K;HH RKW2/-D@D@$9\F(PA)&8#;Q@Y7TQ4T>G
M".:Q<>6%M8F0!5P.0O3TZ5?HH H2V#R/J#!P/M40C7C[N 1_6C[%)'*DP(<Q
MVIAV8^\>#_2K]% '-Z''<0W,$<RRS;8BFYT=/(Z<?-P<XQQZ>E;=];&[MO*5
M@I\Q'R1_=8'^E6:* *,]BTT]U(' \^V$(&.A^;G_ ,>I8K)H[J&4N"([;R<8
MZG(Y_2KM% &=;::\ TX&13]DC9&P/O9 ''Y5'_9MQ':6JPR1&:WG:4;P=K!M
MW''/1OTK5HH RX],F%MLDF0R&[%P2JD#[P;%+=:4;F*^0R ?:71UX/!4+C/X
MK6G10!1TZR-IYS.D2O(1GRRQX [EN31=V]RU[!<VQAS'&Z%9,_Q%3GC_ ':O
M44 94FCM+8S1RRJUQ-,L[-@A=P(P, YQA0.N>](NDO\ V==P8ACDN.Z;B!T
MR2<GI[5K44 96HZ4UU=BXC\MF,7E,LA8#&<@_*>>IXJQ'8F.ZBD5E"1VWD!0
M,=QS].*NT4 9+Z5+_9]G;KY+O;IMWL60@XQE67D?3O27.DRS?993(DT\4)B<
MR%E#9Q\WR]\BM>B@#*N-+=K2VA@6 -"FU6&Y"AQU4@Y ]JTH4>."-))#(ZJ
MSD8W''6GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>cvm_ex992000.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cvm_ex992000.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L .,# 2(  A$! Q$!_\0
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M.U+VQXV:SQ\90^J+3KM^O0]"BD2:))8SN1U#*?4&GU';PI;6T4$?W(T"+GT
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M$3><)&X^[D<= <U"MWEY"EY.]\+UD2$N<%/,P1MZ;=N>>WK72U'#!' K+&N
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<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
